Market Research Logo

Primary Biliary Cholangitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Primary Biliary Cholangitis Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Primary Biliary Cholangitis (PBC) is a rare disease characterized by chronic progressive liver disorder. It majorly affects women and usually occurs in middle age ranging between 30 to 60 years. It is also called as biliary cirrhosis. PBC tends to affect the small bile duct present in the liver. Primary biliary cholangitis is divided into four stages including stage 1 with no significant scarring to stage 4 known as cirrhosis. PBC is triggered by the combination of factors such as autoimmune, genetic, and environmental factors.

Market Dynamics

Increasing number of Food and Drug Administration (FDA) approvals for the drugs to treat PBC is contributing to the market growth. For instance, in May 2016, the U.S. Food and Drug Administration (FDA) approved Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults with an inadequate response to UDCA. Furthermore, in 2016, Ocaliva was assigned fast track designation and orphan drug designation by the U.S. FDA.

Moreover, in February 2018, U.S.FDA granted orphan drug designation (ODD) to Calliditas Therapeutics AB, specialty pharmaceutical company engaged in development of high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in Stockholm, Sweden, for the treatment of Primary biliary cholangitis (PBC).

Furthermore, key players are engaged in conducting clinical trial to develop treatment for primary biliary cholangitis. For instance, in February 2017, Zydus Cadila received the US Food and Drug Administration (USFDA) approval to initiate a Phase-2 clinical trial of Saroglitazar Magnesium (Mg) in patients with Primary Biliary Cholangitis of the liver.

Key features of the study:

  • This report provides in-depth analysis of the primary biliary cholangitis treatment market size (US$ Mn), and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global Primary Biliary Cholangitis Treatment Market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Novartis AG, Bristol-Myers Squibb, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., TARGET PharmaSolutions, Inc., Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Retrophin, Inc., Calliditas Therapeutics AB, and GlaxoSmithKline (GSK) pharmaceuticals.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global Primary Biliary Cholangitis Treatment Market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for Primary Biliary Cholangitis Treatment Market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
  • Global Primary Biliary Cholangitis Treatment Market, By Treatment Type
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid (Ocaliva)
  • Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Primary Biliary Cholangitis Treatment Market, By Region:
  • North America
  • By Country:
  • U.S.
  • Canada
  • By Treatment Type:
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid (Ocaliva)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • By Treatment Type:
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid (Ocaliva)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
  • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • By Treatment Type:
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid (Ocaliva)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • By Treatment Type:
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid (Ocaliva)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • By Treatment Type:
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid (Ocaliva)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • By Treatment Type:
  • Ursodeoxycholic acid (UDCA)
  • Obeticholic acid (Ocaliva)
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
  • Novartis AG,*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Bristol-Myers Squibb.
  • NGM Biopharmaceuticals
  • Lumena Pharmaceuticals, Inc.
  • TARGET PharmaSolutions, Inc
  • Intercept Pharmaceuticals, Inc
  • Teva Pharmaceutical Industries Ltd
  • Retrophin, Inc.
  • Calliditas Therapeutics AB.
  • GlaxoSmithKline (GSK) pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Treatment Type
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Technology Advancements
Pipeline Analysis
Epidemiology
Merger and Acquisition
Regulatory Scenario
Government Initiatives
PEST Analysis
4. Global Primary Biliary Cholangitis Treatment Market, By Treatment Type, 2018 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Ursodeoxycholic acid (UDCA)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Obeticholic acid (Ocaliva)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
5. Global Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2018 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
6. Global Primary Biliary Cholangitis Treatment Market, By Region, 2018 – 2026, (US$ Million)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, By Region, 2017 – 2026
Regional Trends
North America
Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
U.S.
Canada
Europe
Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
North Africa
Central Africa
South Africa
Middle East
Market Size and Forecast, By Treatment Type, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
GCC Countries
Israel
Rest of Middle East
7. Competitive Landscape
Heat Map Analysis
Company Profiles
Novartis AG
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Bristol-Myers Squibb.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
NGM Biopharmaceuticals.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Lumena Pharmaceuticals, Inc,
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
TARGET PharmaSolutions,
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Intercept Pharmaceuticals, Inc
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Retrophin, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Calliditas Therapeutics AB.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
GlaxoSmithKline (GSK) pharmaceuticals.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Analyst Views
8. Section
References
Research Methodology
About us and Sales Contact
*Browse 20 market data tables and 17 figures on “Primary Biliary Cholangitis Treatment Market” - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report